Slow and steady wins this race -- and that is why Flamel Technologies took the more natural approach with basal insulin in developing Basulin. The results in a comparison study with Lantus showed patients, while on Basulin, experienced 50% less hypoglycemic events.
Basulin is a controlled release of human insulin, not an insulin analogue like Lantus. The goal with Basulin is to deliver human insulin in order to reduce the risk of potential immune response which can be created by artificial insulins. Lantus has been the preeminent leader since its introduction in 2000. However, Lantus is an insulin analog, meaning that its molecular structure has been changed slightly, to sustain this long-lasting effect. The long-term effects and safety of insulin analogues have not been established.
In a human study, patients formerly treated with Lantus were then changed to Basulin. On the day prior to replacement of Lantus with Basulin, 11 hypoglycemic events were experienced in the 30 patients receiving Lantus. Once these patients were switched to Basulin for the 14 day trials, an average of only 5.1 hypoglycemic events per day occurred. This result is very encouraging, because hypoglycemia is a severe and commonly observed event in T1DM patients. Here is the billion dollar question (In 2006 over 60% of $8.9 billion was spent on long-acting insulin) -- is this more natural Basulin more fat-loving (like real human insulin) in comparison to the insulin analogue Lantus?
1. Hmmmn...I read the PDF File and this seems to be the only insulin that has begun using nanoparticles in its composition.
Are there any Studies going on now for Basulin?
Is it on the Market?
Posted at 12:12AM on Jun 12th 2007 by BetterCell